First Wave BioPharma Inc's shares are trading lower after the company received topline results from its Phase 2 SPAN trial for the treatment of exocrine pancreatic insufficiency in cystic fibrosis patients. The preliminary data indicates that the primary efficacy endpoint was likely not achieved. The company plans to pursue an End-of-Phase 2 meeting with the FDA in the fourth quarter of 2023.